Organon has acquired 3 companies, including 3 in the last 5 years.
Organon’s largest acquisition to date was in 2024, when it acquired Dermavant Sciences for $1.2B. Organon has acquired in 1 US state, and 2 countries. The Company’s most targeted sectors include medical products (67%) and life science (34%).
30 Hudson Street,
Jersey City, New Jersey
07302
United States,
(551) 430-6000
www.organon.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2024-09-18 |
Dermavant Sciences · Medical Products
Long Beach, California · www.dermavant.com Dermavant Sciences is focused on developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant Science’s medical dermatology pipeline includes earlier-development, late-stage, and commercialized, product candidates that target specific unmet needs in growing immuno-dermatology markets, plaque psoriasis and atopic dermatitis, as well as other immunological and inflammatory diseases. Dermavant Sciences was founded in 2015 and is based in Long Beach, California. |
1,200 | Add-on Acquisition |
Organon
|
Roivant Sciences
|
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
